Vaccinex Reports Second Quarter 2023 Financial Results and Provides Corporate Update
Phase 1/2a SIGNAL-AD Study of Pepinemab in Alzheimer’s Disease Achieves Full Accrual Expect to Complete 12-months treatment in June, 2024...
Vaccine
Advanced Health Intelligence Ltd Signs Collaboration Agreement with IntelliGen FZ-LLC
Highlights AHI enters a second commercial agreement in the UAE.IntelliGen Founders have worked with, and within the Government, Healthcare needs...
BiondVax Reports Second Quarter Financial Results and Provides Business Update
JERUSALEM, Aug. 11, 2023 (GLOBE NEWSWIRE) -- via IBN - BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a biotechnology company focused on...
cbdMD Demonstrates Strong Year-over-Year Performance, Significantly Reducing Net Loss by $30 Million
Charlotte, North Carolina--(Newsfile Corp. - August 10, 2023) - cbdMD, Inc. (NYSE American: YCBD) (NYSE American: YCBDpA), one of the...
Blue Water Biotech and Copay Consultants Collaborate to Build Copay Assistance Programs for Blue Water’s Commercial Products
CINCINNATI, Aug. 10, 2023 (GLOBE NEWSWIRE) -- Blue Water Biotech, Inc. (“Blue Water” or the “Company”), a biotechnology and pharmaceutical...
Inovalon Achieves NCQA HEDIS® Measure Certification for the 23rd Consecutive Year
Inovalon Converged Quality, Cloud Software Empowers More Than 80% of the Nation’s Clinical Outcomes Measurement AnalyticsBOWIE, Md., Aug. 10, 2023...
Ocean Biomedical (NASDAQ: OCEA) Provides Latest Updates on its Broad Programs in Malaria, Fibrosis, and Multiple Cancers
Ocean Biomedical will host a Research and Development Day, Live Q&A with Scientific Co-founders, Dr. Jack A. Elias, MD and Dr....
Vaxxinity Announces Publication of UB-311 Safety, Tolerability, Immunogenicity, and Clinical Efficacy Data from Phase 2a Trial in Alzheimer’s Disease
Phase 2a data published in The Lancet’s eBioMedicine supports further development of UB-311 The paper concludes that UB-311 is the...
IMUNON Reports Second Quarter 2023 Financial Results and Provides Business Update
Advances Non-Viral DNA-Mediated Immunotherapy and Next-Generation Vaccine Programs with Multiple Near-Term Milestones Supported by a Strong Balance Sheet Conference Call...
Vaccitech Reports Second Quarter 2023 Financial Results and Recent Corporate Developments
OXFORD, United Kingdom, Aug. 10, 2023 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company engaged in the...
HOOKIPA Pharma Reports Second Quarter 2023 Financial Results and Recent Business Highlights
HOOKIPA reported positive preliminary Phase 2 data on HB-200 in combination with pembrolizumab in 1st-line setting for advanced head and...
Ocean Biomedical (NASDAQ: OCEA) Share Price Target Now Averaging $18.21, Based on Research and Development Progress in Three Promising Programs Generating Novel Treatment Candidates for Cancer, Malaria, and Fibrosis.
Ocean Biomedical will host a Research and Development Day, Live Q&A with Scientific Co-founders, Dr. Jack A. Elias, MD and Dr....
TFF Pharmaceuticals to Hold Second Quarter 2023 Financial and Business Results Conference Call on August 15, 2023
Company to hold conference call and webcast on August 15, 2023, at 11:00 AM ETFORT WORTH, Texas, Aug. 09, 2023...
Bioz Inc. Has Partnered With Avanti Polar Lipids to Bring Evidence-Based Recommendations to Scientists
PALO ALTO, CA / ACCESSWIRE / August 9, 2023 / Bioz, Inc., a leading AI software company based in Silicon...
Virogentics, Inc. Receives Permit for Export to Africa of the ITV-1 Immunotherapy Solidifying the Scheduled Administration of the Treatment
Reports on Business combination agreement progressALLEN, TX / ACCESSWIRE / August 8, 2023 / Enzolytics, Inc. (OTC PINK:ENZC) (https://enzolytics.com/).Virogentics, Inc....
Alpha Pro Tech, Ltd. Announces Second Quarter 2023 Financial Results
Net sales for the second quarter of 2023 were $16.1 million, down 7.2%, compared to $17.4 million for the second...
IO Biotech Announces Abstract Accepted for Poster Presentation at ESMO Congress 2023
NEW YORK, Aug. 08, 2023 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer...
Cocrystal Pharma Selects Novel Oral Protease Inhibitor CDI-988 as Norovirus Lead
First dual coronavirus-norovirus oral antiviral is scheduled for Phase 1 in healthy volunteers In vitro studies show broad-spectrum activity against...
Emergent BioSolutions Announces Strategic Steps to Strengthen Core Business and Financial Position
Actions bring sharpened focus on MCM and NARCAN® Nasal Spray products Expected to improve operational efficiencies and deliver annual cost...
IO Biotech, Inc. Announces $75 Million Private Placement Financing
Offering includes participation from both new and existing healthcare-dedicated investorsProceeds extend the company’s cash runway into the fourth quarter of...